Barrett&apos;s esophagus: proton pump inhibitors and chemoprevention II. by Richter, J. E. et al.
Ann. N.Y. Acad. Sci. ISSN 0077-8923
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Issue: Barrett’s Esophagus: The 10th OESO World Congress Proceedings
Barrett’s esophagus: proton pump inhibitors
and chemoprevention II
Joel E. Richter,1 Roberto Penagini,2 Daniel Pohl,3 Katerina Dvorak,4,5 Aaron Goldman,5
Edoardo Savarino,6 Patrizia Zentilin,6 Vincenzo Savarino,6 Joshua T. Watson,7
Roy K.H. Wong,7 Fabio Pace,8,9 Valentina Casini,8 David A. Peura,10 Shoshana Joy Herzig,11
Takeshi Kamiya,12 Iva Pelosini,13 Carmelo Scarpignato,13 David Armstrong,14
Kenneth R. DeVault,15 Paolo Bechi,16 Antonio Taddei,16 Giancarlo Freschi,16
Maria Novella Ringressi,16 Duccio Rossi Degli’Innocenti,17 Francesca Castiglione,17
Emmanuella Masini,18 and Richard H. Hunt19
1Department of Medicine, Temple University, Philadelphia, Pennsylvania. 2Dipartimento di Scienze Mediche, Universita` degli
Studi and Fondazione IRCCS “Ca Granda,” Ospedale Maggiore Policlinico, Milan, Italy. 3Department of Internal Medicine,
University Hospital, Zu¨rich, Switzerland. 4Department of Cell Biology and Anatomy, College of Medicine, Tucson, Arizona.
5Arizona Cancer Center, The University of Arizona, Tucson, Arizona. 6Division of Gastroenterology, Department of Internal
Medicine, University of Genoa, Genoa, Italy. 7Department of Medicine, Gastroenterology, Walter Reed Army Medical Center,
Washington, District of Columbia. 8Gastrointestinal Unit “Bolognini” Hospital Seriate (BG), Milan, Italy. 9University of Milan,
Milan, Italy. 10University of Virginia Medical Center, Charlottesville, Virginia. 11Division of General Medicine, Beth Israel
Deaconess Medical Center, Boston, Massachusetts. 12Department of Gastroenterology and Metabolism, Nagoya City
University Graduate School of Medical Sciences, Nagoya, Japan. 13Laboratory of Clinical Pharmacology, Division of
Gastroenterology, Department of Clinical Sciences, School of Medicine and Dentistry, University of Parma, Parma, Italy.
14Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, Canada. 15Mayo Clinic College of
Medicine, Jacksonville, Florida. 16Department of Medical and Surgical Critical Care, Unit of Surgery, University of Florence,
Florence, Italy. 17Department of Medical and Surgical Critical Care, Unit of Human Pathology, University of Florence, Florence,
Italy. 18Department of Pharmacology, University of Florence, Florence, Italy. 19Farncombe Family Digestive Disease Research
Institute, Department of Gastroenterology, McMaster University Health Science Centre, Hamilton, Ontario, Canada
The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett’s esophagus includes
commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett’s
esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release
PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-
inflammatory drugs (NSAIDs), and new PPIs.
Keywords: pH testing; 48-h acid reflux monitoring; ACG guidelines; PPI therapy; Symptom Association Probability;
GERD; bile acids; Bilitec probe; functional dyspepsia; functional heartburn; Barrett’s esophagus; acid suppression;
NERD; ilaprazole; tenatoprazole; CMA omeprazole; rabeprazole; dexlansoprazole; fundic glands polyp; Clostridium
difficile; erosive esophigitis; pharmacokinetic changes; GABAB; baclofen; TLESR; nocturnal acid breakthrough; COX-2
inhibitors; AspECT trial; STU-Na; API-023
Concise summaries
• In nonerosive reflux disease (NERD) patients,
refractory toprotonpump inhibitors (PPIs) and
undergoing 96-h wireless pH monitoring, off-
and on-therapy testing may be useful.
• The performance of the catheter-free wireless
pH capsule in measuring esophageal acid expo-
sure has been validated in simultaneous con-
trolled trials. It can be now recommended to
perform pH tests on patients with a “low prob-
ability” of GERD and persistent symptoms on
PPIs “off-therapy” for at least seven days. In this
scenario, acid measurement alone is sufficient
because nonacid reflux is only relevant during
acid suppression.
doi: 10.1111/j.1749-6632.2011.06048.x
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• pH-impedance is currently the diagnostic tool
of choice in the evaluation of patients with per-
sistent symptoms on PPI therapy.
• Themajor goal of bile and acid testing should be
to evaluate the type of reflux, so that the patients
withmixed reflux canbe identified and followed
more closely, because these patients have a po-
tentially increased risk to develop dysplasia and
esophageal adenocarcinoma.
• No therapy has been shown to be highly effec-
tive in patients with functional dyspepsia (FD).
Patients with an overlap of functional heart-
burn (FH) and dyspeptic symptoms respond
less than patients with NERD and hypersensi-
tive esophagus to antisecretory therapy, and this
seems to sustain the fact that patients with func-
tional GI disorders are less likely to respond to
antisecretory drugs.
• Given some of the differences that have been
found between long-segment BE patients and
short-segment BE patients, it seems logical
that long-segment BE patients would require
a higher dose of PPI to achieve adequate
intraesophageal acid suppression, but this is
still to be shown. Esophageal pH monitoring
is required to determine the appropriate PPI
dose.
• The low response rate of NERD to PPIs is
probably a feature of true NERD patients,
whereas FH patients should not respond at
all to these drugs. In patients “refractory” to
PPI therapy, the underlying pathogenesis of
symptoms needs to be reevaluated, preferably
by pH-impedancemonitoring, conducted “off”
therapy.
• Developing PPIs with longer half-lives or ones
that incorporate delivery technologies to pro-
long their absorption are rational ways to im-
prove their pharmacology and effectiveness.
The only one of these newer drugs currently
available in the United States, dexlansoprazole-
MR,doeshavemore convenientdosing, a longer
duration of action, consistent clinical efficacy,
and excellent safety and tolerability.
• The clinical implications of long-term use of
PPIs can best be understood by calculating
numbers-needed-to-harm, using the estimates
of relative risk and unexposed incidence rate
of the complication, from the major studies in
each area.
• Newer PPIs, formulated for delayed release ap-
pear to reduce nocturnal intragastric acidity to a
greater extent than current delayed release PPIs,
when given once-daily. On the other hand, im-
mediate release PPIs have several advantages
over enterically-coated PPIs. They have out-
standing nocturnal acid control when given
twice daily and can provide very good acid
support when given at bedtime. An additional
advantage is the ability to take the medication
independent of food consumption. Prokinetic
agents may be considered as a valuable addition
to the treatment of Barrett’s patients. Taking
into account the comorbidities and consequent
cotherapies often needed in obese patients, the
low propensity for drug-to-drug interactions of
rabeprazolemakes this PPI particularly suitable
for these patients with any acid-related diseases.
• Published studies on baclofen, a GABAB ago-
nist, relate to its effects on the lower esophageal
sphincter (LES) and esophageal reflux in nor-
mal and reflux patients. However, although
baclofen has been shown to decrease TLESRs
specifically in the postprandial state, there are
a few studies to suggest that it may be effective
in supine reflux and duodenogastroesophageal
reflux.
• No trial has definitely shown the efficacy of any
kind of chemoprevention in BE. However, rel-
evant but not decisive clinical and experimen-
tal data stand for the association aspirin/PPIs
to be potentially capable of a synergistic
effect.
• In spite of uncertainties, the prospect of truly
once-daily antisecretory drugs is now real, and
they offer a lack of significant food interaction
and an overall consistent acid control with less
pulsatile acid exposure and improved control
of nighttime acid secretion with fewer episodes
of so-called “nocturnal acid breakthrough.”
The potential benefit of this new generation
of antisecretory drugs is to prevent GERD
complications, and the progression of Barrett’s
esophagus (BE).
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1. Should 48-h acid reflux monitoring be
strongly recommended in patients on PPIs
with persistent GERD symptoms?
Joel E. Richter
jrichter@temple.edu
Thewireless pH system (Bravo capsule, Given Imag-
ing, Israel) uses a radiotelemetry pH-sensing cap-
sule that is attached to the mucosa of the distal
esophagus. It is positioned by endoscopy 6 cmabove
the squamocolumnar junction or can be placed af-
ter traditional manometry 5 cm above the proxi-
mal border of the LES. The capsule simultaneously
measures pH and transmits data via a radiofre-
quency signal to a pager-sized receiver clipped to
the patient’s belt. The performance of the catheter-
free wireless pH capsule in measuring esophageal
acid exposure has been validated against catheter-
based antimony pH electrode systems in simultane-
ous controlled trials.1
The main advantages of the wireless system are
the lack of a transnasal catheter and that its position
can be fixed. Tolerability is better with the wire-
less system when compared with catheter-based pH
monitoring in both uncontrolled observations and
randomized comparison studies.2 As a result, pa-
tients can be more active, eat regularly, sleep better,
and attend work or other activities that may other-
wise aggravate their GERD symptoms. Tolerability
also allows the study to be done for up to 48 h
routinely, and sometimes longer, if the battery is
changed. Not surprisingly, longer studies are bet-
ter for identifying abnormal acid exposure times
(AETs) or reflux symptom relationships when com-
pared to the traditional 24-h study.3,4 However, it
must be remembered that the capsule with its an-
timony pH electrode is only accurate in measuring
acid reflux and should be done with the patient off
PPIs for one to two weeks.
Many studies have shown that patients with typ-
ical or atypical symptoms on PPIs do not have acid
reflux. Despite the enthusiasm for nonacid reflux,
an average of only 30–40% have increased episodes
of nonacid (pH 4–6) reflux, with or without symp-
tom correlation. Thus, 50–60% of patients on PPIs
have normal studies, even if impedance testing is
performed.5 In these settings, we are left with the
unsettling question of what to do with PPI ther-
apy. Should the PPIs be continued because GERD
is controlled and symptoms have another etiology?
Or, perhaps the patient never had GERD, and there-
fore PPIs can be stopped while alternative diagnoses
are evaluated? The latter situation is particularly im-
portant in patients with atypical GERD symptoms,
where the lack of acid reflux allows the gastroen-
terologist to refer these patients back to ENT, lung,
Figure 1. All forms of pH testing can be done, but, clinically, the Bravo capsule is usually preferred because of its tolerability and
ease for recording acid reflux for at least 48 h. If pH testing while off PPIs is negative (normal acid exposure time and a negative
symptom–reflux association), GERD is very unlikely. Patients with heartburn as a predominant symptommay be labeled as having
functional heartburn, whereas those with atypical symptoms will require workup for other etiologies.
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or cardiac specialists for evaluation of alternative
diagnoses.
As shown in Figure 1, many experts now rec-
ommend performing pH tests on patients with a
“low probability” of GERD and persistent symp-
tomswhileusingPPIs “off-therapy” for at least seven
days.5,6 In this scenario, acid measurement alone is
sufficient because nonacid reflux is only relevant
during acid suppression.
2. Should use of a wireless system with
recording of off- and on-therapy testing be
recommended for patients with normal
endoscopy that do not respond to PPI
therapy?
Roberto Penagini and Andrea Tenca
roberto.penagini@unimi.it
Thewireless system for pHmonitoring has some ad-
vantages over the traditional catheter-based system.
Owing to themore prolonged period of recording, it
has a higher likelihood of detecting symptom/reflux
association, especially when infrequent symptoms
are present, as well as pathological esophageal AET.
Inaddition, it allows endoscopic andpHmonitoring
assessment in the same session. Finally, it allows pH
monitoring in patients who refuse or do not toler-
ate the traditional pH or pH+ impedance catheter-
based testing. These patients represent around 8%
of all patients referred for pH testing.
A few studies have investigated if it was feasible to
study patients both off and on PPIs during the same
test.Calabrese et al.7 assessed24patientswithNERD
responding toPPIs duringonedayoff and three days
on PPI, randomizing the patients to omeprazole, 20
mg; pantoprazole, 40 mg; or lansoprazole, 30 mg
once daily. They found that by the second day on
PPI, AET was normalized in 7/8 patients with each
of the three drugs.
Two studies have involved patients refractory to
PPIs8,9: Hirano et al.8 studied 18 NERD patients
during one day off and three days on rabeprazole,
20mg twice daily. One patient was excluded for pre-
mature capsule detachment. On day 1, 9/17 patients
had pathological AET and 15/17 had symptoms,
four of whom had a positive symptom index (SI).
On day 4, one patient only had both pathological
AET and positive SI; all the others had normal AET,
but 11 still had symptoms. Garrean et al.9 studied
Table 1. Patients with capsule detachment during 96-h
wireless pH monitoring (percentage in parentheses)
≤ Day 2 Day 3 Day 4
Hirano et al.8 0/18 1/18 (6%) 1/18 (6%)
Scarpulla et al.10 5/83 (6%) 26/83 (31%) 14/83 (17%)
Calabrese et al.7 0/24 0/24 0/24
Garrean et al.9 0/60 4/60 (7%) 5/60 (8%)
Grigolon et al.11 3/57 (5%) 9/57 (16%) 9/57 (16%)
60 patients, 49 of whomhadNERD during two days
off and two days on either rabeprazole, 20 mg, or
omeprazole/sodium bicarbonate, 40mg twice daily.
Twenty studies were discarded, either because of
capsule detachment or loss of data transmission.
On day 1 or 2, 14/40 patients had pathological AET,
and 36/40 had symptoms; in 18 of them the symp-
tom association probability (SAP) was positive. On
day 4, all patients apart from 1 had a normal AET;
however, 28 were still symptomatic, and SAP was
positive in only four of them. These data confirm
that most patients refractory to PPIs either do not
have GERD or are not only sensitive to acid.
In conclusion, in NERD patients refractory to
PPIs and undergoing 96-h wireless pH monitoring,
off- and on-therapy testing may be useful. Clini-
cians should be aware, however, of two limitations:
a considerable number of capsules may detach dur-
ing day 3 or 4 (Table 1), thus decreasing the power
of on-therapy testing; and the role of weakly acidic
reflux cannot be assessed.
3. Are there therapeutic implications for
impedance testing in patients
unresponsive to PPI therapy?
Daniel Pohl
daniel.pohl@usz.ch
GERD is a prevalent clinical condition occur-
ring in 10–30% of the population. The major-
ity of patients respond to PPI therapy. However,
community-based studies have shown that approx-
imately 40% of patients supplement their prescrip-
tion PPI with oral antacids and/or H2-receptor
antagonists, indicating that partial or complete ther-
apy failure may occur in a significant proportion of
patients.
The single most important reason for a failing
PPI is awrongdiagnosis ofGERD.Theprimary goal,
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therefore,must be to validate the diagnosis ofGERD
in a patient presenting with PPI failure. According
to the Montreal classification, GERD is diagnosed
on the basis of refluxate entering the esophagus,
which causes symptoms and/or mucosal damage.
In the absence of erosions in the esophagus, which
are rarely present in a patient on PPI treatment,
an association between patient symptoms and re-
flux should be documented. Objective parameters,
such as an abnormal number of reflux episodes or
AET, support the diagnosis of GERD. Because es-
tablishing a true diagnosis of GERD is key, the most
appropriate diagnostic tools should be used.
Even with perfect acid control, patients may
still experience reflux symptoms. Weakly acidic or
nonacidic reflux may cause typical (and atypical)
symptoms of reflux disease. Up to 70%of heartburn
episodes in PPI refractory patients may be associ-
ated with weakly acidic reflux, and only esophageal
proximal extent has been identified as an important
factor in reflux perception.12 pH-impedance allows
the association between weakly acidic/nonacidic re-
flux and patient symptoms, as well as validation of
acid reflux by acid reflux episodes, thereby differen-
tiating reflux disease from functional disorders that
should be considered outside the realm of GERD
and treated differently.13
Few outcome studies are available based on find-
ings from pH-impedance testing. Mainie et al. fol-
lowed 19 patients whowere refractory to PPI twice a
day that underwent a successful laparoscopic Nissen
fundoplication. Before surgery, 18 of the 19 patients
were found to have a positive symptom associa-
tion on MII-pH monitoring (14 with nonacid and
4 with acid reflux). After a mean follow-up of 14
months, 16 of the 18 patients with a positive symp-
tom association were asymptomatic.14 Becker et al.
assessed 56 patients with persistent symptoms on a
once daily dose of PPI and abnormal MII-pHmon-
itoring results. Most of these patients had a positive
symptom association, and later demonstrated a sig-
nificantly higher response rate to increasing the PPI
dose to twice a day compared to patients with nor-
mal MII-pH monitoring results.15 Del Genio et al.
prospectively assessed the outcomes of laparoscopic
Nissen fundoplication in patients who were PPI
nonresponsive or noncompliant. All 62 surgically
treated patients had a positive MII-pH monitoring
result. The overall patient satisfaction rate was
98.3%, andnodifferenceswere found in clinical out-
comes based on preoperative MII-pH or manome-
try results.16
In conclusion, pH-impedance is currently the di-
agnostic tool of choice in the evaluation of patients
Figure 2. A therapeutic/diagnostic tree in the assessment of patients with persistent symptoms on PPI therapy.
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with persistent symptoms on PPI therapy. A thera-
peutic/diagnostic tree in the assessment of patients
with persistent symptoms on PPI therapy is sug-
gested in Figure 2.
4. What can be currently expected from
bile and acid reflux testing?
Katerina Dvorak and Aaron Goldman
kdvorak@email.arizona.edu
The major risk factor for BE development is gas-
troesophageal reflux disease (GERD). Although the
importance of gastroesophageal reflux in the patho-
genesis of BE is undisputed, it is not yet clear which
elements in the refluxate are responsible for meta-
plastic change to the intestinal epithelium.17 Hy-
drophobic bile acids are associated with gastroin-
testinal cancers, including colon cancer, and they are
considered to play also a major role in BE and EAC
development.17 A majority of BE patients and es-
pecially those with dysplastic BE have mixed reflux
(bile and acid). Importantly, the damaging effects
of gastric acid and bile are synergestic. Our recent
studies revealed that a combination of bile acids and
weak acid induces DNA damage that is significantly
higher compared to damage induced by individual
agents alone. Therefore, simultaneous bile and acid
testing is important.
Pathologic exposure to duodenal refluxate, as
measured by Bilitec monitoring, was observed in
22.2% of patients with esophagitis (EE), 54.5%
of patients with BE, and 78.6% of patients with
EAC, indicating the importance of bile acids in EAC
pathogenesis.18 Duodenoesophageal reflux is muta-
genic as shownby in vivo experiments usingBigBlue
rats19 and Big Blue mice.20 In agreement with this
conclusion, Fein et al. also demonstrated that duo-
denoesophageal reflux induces EAC without exoge-
nous carcinogen. In addition, another study showed
that the typical injuries and cellular changes seen in
severe reflux EE, that may lead to development of
BE, are induced in rats by continuous perfusionwith
bovine bile treatment for only four weeks. Overall,
the evidence indicates that bile acids contribute to
the development of BE and EAC. A diet high in fat
increases the release of bile acids into the gastroin-
testinal tract, thus also increasing the concentration
of bile acids in the refluxate.
However, currently only pH monitoring and
management of acid reflux is the main strategy to
evaluate and treat patients with GERD and BE. The
probes tomeasure exposure to acidwere successfully
developed and they can accurately measure changes
in esophageal pH. By contrast, the reflux of bile is
not routinely monitored and the studies evaluating
actual bile reflux are not common. Themajor prob-
lem is that the methods that are used to study bile
reflux are cumbersome and have limitations.
The presence of bile in the esophagus may be de-
tected spectrophotometrically by a miniature fiber
optic system (Bilitec probe). This method of mea-
suring bilirubin absorbance can be combinedwith a
pH probe and allows prolongedmonitoring of duo-
denal reflux. Direct aspiration studies of refluxate
followed by gas or liquid chromatography are the
most precise methods for the detection of the con-
centration and individual bile acids present in the
refluxate. However, these methods are not useful
for routine monitoring, because they are demand-
ing and require special instruments.
Impedance is another method that can mea-
sure the frequency, duration, and extent of reflux
episodes. This method detects gastroesophageal re-
flux events on the basis of a change in resistance
to the flow of an electrical current between pairs of
electrodes. When this method is combined with pH
monitoring, it is possible to determine acid, weak
acid, and alkaline reflux. However, thismethod can-
not determine the composition of refluxate and/or
the concentration of bile acids in the esophagus.
Importantly, the activity of bile acids depends
on the pH. There are marked differences in the
behavior of bile acids depending on the pH of
the solution. At low pH in the stomach (pH ∼2),
the majority of bile acids present in the reflux-
ate irreversibly precipitate.Only taurine-conjugated
bile acids are soluble at this pH; however, taurine-
conjugated bile acids constitute only ∼20% of total
bile acids present in the refluxate. At a higher pH
(∼4–7) glycine-conjugated and unconjugated bile
acids are soluble, unionized, and thus they inter-
act with esophageal mucosa and cause cell damage.
This pH zone is considered the most dangerous,
because the combined effects of bile acids and acid
lead to altered signaling, increased DNA damage,
and mutations.
Molecular imprinting using a biosensor specific
for bile acid is a promising novel technique that
can be developed to detect bile acids present in the
esophagus. The principle of this technology involves
selection of a polymer that is capable of forming
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noncovalent interactions with a template molecule
such as glycocholic acid.21 Currently, however, the
Bilitec probe in combination with pH monitoring
is the only approach to monitor true reflux of bile
and acid. There are five major outcomes that can be
expected: (1) no reflux, (2) reflux of acid only, (3)
reflux of bile only, (4) weak acid and bile reflux, and
(5) acid and bile reflux.
In summary, the major goal of bile and acid test-
ing should be to evaluate the type of reflux, so
that patients with mixed reflux can be identified
and followed more closely; potentially these pa-
tients have increased risk of developing dysplasia
and esophageal adenocarcinoma.
5. Are patients with dyspepsia less
responsive to PPI therapy?
Edoardo Savarino, Patrizia Zentilin, and Vincenzo
Savarino
edoardo.savarino@unige.it
FD is a frequent disorder in Western countries.22
In recent years many definitions of dyspepsia have
been attempted and, actually, the last iteration of
the Rome III criteria defined FD as the presence of
one or more of the following symptoms (epigastric
pain, epigastric burning, postprandial fullness, early
satiation) thought to originate in the gastroduode-
nal region, in the absence of any organic, systemic,
or metabolic disease that would otherwise likely ex-
plain the symptoms.23
The pathophysiology of FD is unclear, but it is
likely to be multifactorial.22 Putative mechanisms
include overlapping disorders of upper gastroin-
testinal motor and sensory function. Among them,
delayed gastric emptying, impaired fundic accom-
modation to a meal, altered visceral sensation (e.g.,
increased gastric hypersensitivity tomechanical dis-
tention, and duodenal hypersensitivity), Helicobac-
ter pylori induced gastritis, and increased sensitivity
to acid infusion have been encountered in many
patients with FD. Therefore, the main therapeu-
tic approaches to its management are represented
by acid inhibition, prokinetic drugs, and H. pylori
eradication (Fig. 3).
However, the role of acid suppression is contro-
versial, and randomized controlled trials evaluating
the efficacy of antisecretory therapy have given con-
flicting results.22,24 A meta-analysis of controlled,
Figure 3. Treatment options for functional dyspepsia.
randomized trials with PPIs in FD reported that
this class of agents was superior to placebo with a
number needed to treat (NNT) of 7. In particular,
four trials compared PPI therapy with placebo and
antacids in 2,164 patients with uninvestigated dys-
pepsia. PPI therapy was more effective (RR, 0.65;
95% confidence interval [CI], 0.55–0.78), with a
NNT of 5 (95% CI, 4–7). Eight trials compared
PPI therapy with placebo in 3,293 patients with
nonulcer dyspepsia. PPI therapy was significantly
superior to placebo with a NNT of 9. The lower
rate of response compared with that obtained in
patients with uninvestigated dyspepsia was due to
the exclusion of patients with organic dyspepsia by
endoscopy, because these latter ones respond sat-
isfactorily to PPIs. Anyway, there was significant
heterogeneity between results, and the major prob-
lem with these trials remains potential misclassi-
fication bias regarding GERD. In a more recent
meta-analysis, Wang et al.25 evaluated a total of
seven studies consisting of 3,725 patients analyzed.
There was a modest but statistically significant dif-
ference in symptom relief in FD patients receiving
PPIs (40.3%) compared with those given placebo
(32.7%) (RRR, 10.3%; 95% CI, 2.7%–17.3%). The
estimated NNT was 14.6 patients (95% CI, 8.7–
57.1). This finding was consistent across different
doses of PPIs and the patients’ status of H. pylori
infection.
It is relevant to note that a large placebo effect has
been documented in many trials aimed at treating
FD, which can range from 5% to 85% of patients,
with an average value of about 40%.22,24,25 It has
been speculated that this may be due to variance in
trial duration, patient selection, recruitment issues,
number of subjects included in the study, and other
study design factors. Finally, we have recently pub-
lished a large prospective study,26 where patients
120 Ann. N.Y. Acad. Sci. 1232 (2011) 114–139 c© 2011 New York Academy of Sciences.
Richter et al. Barrett’s esophagus: PPIs and chemoprevention II
Figure 4. Treatment response to PPIs of patients with nonerosive reflux disease, hypersensitive esophagus, and functional
heartburn.
with FH, identified by means of impedance-pH
monitoring, had a high association with dyspep-
tic symptoms, and these results showed them to
be less responsive to PPI treatment than patients
with pH-POS NERD and hypersensitive esophagus
(Fig. 4). This finding seems to confirm the poor
response of FD to PPIs.
In conclusion, no therapy has been shown to
be highly effective in patients with FD. PPIs seem
to be more effective than placebo in several meta-
analyses, but this occursmainly indyspeptic patients
complaining of epigastric pain and burning, even if
the degree of treatment response appears to be from
mild to moderate. Patients with an overlap of FH
and dyspeptic symptoms respond less well than pa-
tients with NERD and hypersensitive esophagus to
antisecretory therapy, and this seems to sustain the
fact that patients with functional GI disorders are
less likely to respond to antisecretory drugs. Other
treatments have to be adopted.
6. Should the dose of PPI be the same for
short- and long-segment Barrett’s
esophagus?
Joshua T. Watson and Roy K.H. Wong
Joshua.watson5@us.army.mil
BE is a consequence of chronic acid reflux, andmany
patients with BE are placed onhigh-dose PPIs indef-
initely to adequately control reflux symptoms or to
achieve adequate acid suppression. Some gastroen-
terologists have postulated that achieving adequate
acid suppression may be more difficult in long-
segment BE patients as opposed to short-segment
BE patients. As such, BE patients are commonly
prescribed high dosages of PPIs; however, with the
mounting concerns about the potential negative
consequences of long-term, high-dose PPIs, such
as inhibition of bone resorption, small bowel bac-
terial overgrowth, enteric infections, bloating, and
abdominal pain, gastroenterologists must take an-
other look at their use of PPIs and ask, Are we using
too much?
Given some of the differences that have been
foundbetween long-segment and short-segmentBE
patients, it seems logical that long-segment BE pa-
tients would require a higher dose of PPI. First, in
a study by Loughney et al.,27 they found that long-
segment BE patients hadweaker LESs and decreased
distal esophageal peristaltic contractions compared
to short-segment BE patients and controls, which
could contribute to a greater reflux diathesis in the
long-segment BE patients. They also showed that
long-segment BE patients have significantly higher
Johnson–DeMeester (JD) scores than patients with
short-segment BE or controls. Interestingly, this
trendheld true even at 0 cm from theLES,where one
would think that the groups may have more simi-
lar acid reflux exposure. Similar trends were also
seen for percent total reflux, percent upright reflux,
and percent supine reflux with long-segment BE
having a greater degree of both upright and supine
reflux than short-segment BE patients. This study
and others have thus suggested that long-segment
BE patients tend to have weaker LESs, decreased
distal esophageal peristaltic contractions, and a
greater degree of acid reflux.
Fass et al. later showed that there was a direct
correlation between intraesophageal acid exposure
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and the length of Barrett’s mucosa.28 They demon-
strated that the greater percentage of total time the
esophageal pH is less than 4, the longer the Barrett’s
segment tends to be. This trend was also seen for
percent upright time pH < 4 and percent supine
time pH < 4. Thus, they concluded that the du-
ration of esophageal acid exposure is an impor-
tant contributing factor in determining the length
of Barrett’s mucosa. Given the correlation between
upright and supine reflux, it is also likely that both
nocturnal and diurnal esophageal acid exposure are
important in determining the length of BE as well.
Other studies have also implicated duodenogastroe-
sophageal reflux in the development of BE and have
shown that long-segment BE patients tend to have
more duodenogastroesophageal reflux than short-
segment BE patients.
Overall, existing studies suggest that long-
segment BE patients tend to have less competent
LESs, longer hiatal hernias, greater esophageal acid
exposure, and a greater degree of duodenogastroe-
sophageal reflux. However, what is yet to be de-
termined is if these factors translate clinically into
long-segment BE patients requiring higher doses
of PPI than short-segment BE patients to achieve
adequate intraesophageal acid suppression. Only a
few studies have broached this question, most of
which have done so indirectly. The fact that achiev-
ing symptomatic control in BE patients does not
predict normalization of intraesophageal acid has
beenwell established.Outau-Lascar et al.performed
a study in which BE patients’ dose of PPI was es-
calated until symptom control was achieved; then
24-h ambulatory pH monitoring was performed.
They found that the length of Barrett’s mucosa did
not predict those who were going to have patho-
logic reflux despite symptom control.29 As in many
studies that have looked at PPI dosing, they based
the PPI dose on symptoms, not on Barrett’s length
or pH monitoring results; so, it is unclear if treat-
ing based on normalization of pH would have
yielded different results. In another study by Fass
et al.,30 BE patients were treated with high-dose PPI
(omeprazole, 40mg twice daily). They foundno dif-
ference in the rates of failure to achieve acid control
between short-segment and long-segment BE pa-
tients. However, they only enrolled short-segment
BE patients with Barrett’s mucosa of at least 2 cm in
length and long-segment BE patients with Barrett’s
mucosa of 6 cm or fewer. Wani et al. also placed
BE patients on high-dose PPI therapy and then
performed 24-h pH testing.31 With patients taking
rabeprazole, 20 mg twice daily, they noted that the
length of Barrett’s mucosa was not significantly dif-
ferent between those with normal pH profiles and
those with abnormal pH profiles. While these stud-
ies suggest that there is no difference between short-
segment and long-segment BE patients with regard
to the difficulty in achieving adequate acid suppres-
sion, no study has directly compared the dose of
PPI needed to achieve normal intraesophageal acid
exposure in short segment BE patients versus long-
segment BE patients.
A study is currently in progress at Walter Reed
Army Medical Center that will hopefully provide
more insight into this area. Patients with BE and
with gastroesophageal junction–specialized intesti-
nal metaplasia are being enrolled and started on,
or switched to, omeprazole, 20 mg once daily. After
being on this dose for at least one week, patients fill
out a symptom questionnaire and undergo an EGD
with placement of a Bravo pH monitoring capsule.
Day 2 data from the Bravo pH study are used to
calculate a JD score and to assess percent time that
the esophageal pH is less than 4.2%. If patients have
a normal pH study, defined as having an esophageal
pH < 4 for less than 4.2% of the time and a normal
JD score, they are considered adequately controlled.
If, however, they have an abnormal pH study, the
dose of omeprazole is increased to 20mg twice daily.
Again, after at least a week on the increased dose,
they fill out a symptom questionnaire and undergo
a second EGD with Bravo capsule placement. Thus
far, we have completed data on 26 patients: 6 with
ultrashort segments, 13 with short segments, and 7
with long segments. As with most BE studies, the
patients are mostly Caucasian (88%) and male
(77%), and prevalence of hiatal hernias is high
Figure 5. Bravo pH score for omeprazole, 20 mg.
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Figure 6. Change in Bravo pH score: single- vs. double-dose
PPI.
(85%). No differences between the groups reach
statistical significance at this time, but 2/7 (29%)
long-segment BE patients have required twice daily
dosing compared to 3/13 (23%) short-segment BE
patients and 1/6 (17%) ultrashort-segment BE pa-
tients. Surprisingly, 20/26 (77%) patients overall
have been controlled on once daily dosing (Fig. 5),
and only one patient has not been adequately con-
trolled on twice daily dosing (Fig. 6). These early
data show that normalization of intraesophageal
pH can be achieved in a significant percentage of
patients taking omeprazole, 20–40 mg daily, which
suggests that BE patients may require lower doses of
PPIs than previously thought. Also, despite signif-
icant pathophysiologic differences that have been
demonstrated between short-segment and long-
segment BE patients, there is no evidence so far that
long-segment BE patients routinely require higher
PPI doses than short-segment BE patients. Larger
numbers may be needed to show a difference be-
tween the two groups. Finally, our study and sev-
eral other studies have suggested that esophageal
pH monitoring may be required in BE patients to
determine the appropriate PPI dose.
7. Is a low response to PPIs a challenge for
the treatment of patients with NERD or of
those classified as patients with functional
heartburn? Should pathogenesis of
symptoms be reevaluated in these cases?
Fabio Pace and Valentina Casini
fabio.pace@unimi.it
NERD is at present defined according to the Vevey
Working Groups, as follows: “NERD is a subcate-
gory of GERD characterized by troublesome reflux-
related symptoms in the absence of esophageal mu-
cosal erosions/breaks at conventional endoscopy
andwithout recent acid-suppressive therapy.”32 The
question posed by the title may be split into two
more specific ones: do NERD patients respond to
PPI similarly to ERD patients? And should NERD
nonresponders be further investigated (by pH or
pH-impedance monitoring)?
Concerning the first issue, it has been known for
many years that NERD patients, for the most part,
tend to respond to PPI therapy less effectively; as
an example, Dean et al. have shown in a systematic
review of the literature that the PPI symptomatic
response pooled rate was 36.7% in NERD patients
and 55.5% in those with erosive EE.33 The lower
response rate inNERDcouldbedue tooneof several
factors: it is possible that the symptoms in these
patients have nothing to do with GERD and are
related to other factors. In particular, becauseNERD
is a negatively defined clinical entity, it is possible
that a percentage of so-called NERD patients are
rather patients affected by FH, which by definition
does not respond to PPI therapy.34
To overcome the possible influence of an invol-
untary inclusion of FH patients, we designed a ther-
apeutic study on GERD patients with typical symp-
tomswith andwithout erosive EE. The study started
with a two-week period of high-dose omeprazole,
20 mg twice daily (the so-called omeprazole test).
Patients responding to this test period entered an
acute phase (3 months) of treatment with any avail-
able PPI at a standard dose. In this way we pre-
sumably excluded patients not responding to PPI
therapy, that is, FH by definition; 577 patients
with heartburn were recruited, 306 with EE and
271 without (NERD). Of them, 519 (89.9%) had
a positive PPI test, with a greater response in EE
patients (96.4%) compared with NERD (82.6%)
(P = 0.011). Both the percentage of completely
asymptomatic patients and the reduction of heart-
burn intensity at 3 months were significantly higher
in the EE comparedwithNERDpatients (P < 0.01).
The study suggests therefore that “true” NERDmay
in fact have a genuine lower response to PPIs, that
is, not due to misdiagnosis.
Concerning the second question as to whether
NERD patients refractory to PPI therapy should
be further investigated by esophageal pH moni-
toring or by esophageal pH impedance (pH-IM),
a recent position paper by the ROME 3 Working
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Groups has clarified that either examinations can be
performed, but necessarily off-therapy. We would
like to recall our own experience,35 conducted on
460 consecutive outpatients referred to our labo-
ratory to undergo pH-IM, largely due to refrac-
toriness to PPI therapy. In this retrospective study
we found that pH-IM resulted positively in 45%
of patients with a negative pH monitoring (67%
of the total), leading to a change in the treatment
in about 47% of cases. Thus, pH-IM, and not pH-
monitoring alone, was able to substantially increase
the diagnostic yield. On the basis of this experience,
we recommend that NERD patients refractory to
PPI therapy undergo pH impedance, possibly “off”
therapy.
Tofinally answer the initial question,wemay con-
clude that the low response rate of patients with
NERD to PPIs is probably a feature of actual NERD
patients, whereas FH patients should not respond at
all to these drugs. When a NERD patient is “refrac-
tory” to PPI therapy, the underlying pathogenesis
of symptoms needs to be reevaluated, preferably by
investigating the reflux pattern by pH-impedance
monitoring, conducted “off” therapy.
8. What is to be expected from the
“dual-release delivery” action of newly
developed PPIs?
David A. Peura
dap8v@virginia.edu
Pharmacologic treatment for GERD is directed at
acid suppression, and PPIs have emerged as the
medication class of choice. PPIs irreversibly block
the final step of acid secretion by binding to the pro-
ton pump, and secretion can only be restored when
newpumps are activatedor synthesized. In addition,
PPIs only inhibit active proton pumps, and activa-
tion largely occurs by eating food. Not all pumps
are activated during a meal, so later food intake
will stimulate dormant pumps. Also new pumps
are continually regenerated throughout the day. Be-
cause all PPIs share the same mechanism of action
and all have short half-lives (approximately one to
two h), the potential for subsequent acid secretion
exists when dormant or newly regenerated pumps
are activated after drug concentrations fall below
therapeutic levels. Because food is the primary stim-
ulus for pump activation, PPIs need to be taken at
mealtime (usually 30–60 min before breakfast) to
ensure maximum pharmacodynamic (PD) effect.
The short half-life and requirement for meal-timed
administration are inherent pharmacologic limita-
tions of the PPI class that likely explain compliance
and adherence-related persistent or breakthrough
symptoms in as many as 40% of regular PPI users.
Strategies to extend the duration of action (and
AUC) of PPIs include administering a higher dose of
medication, using a more slowly metabolized enan-
tiomer, or dosing medication twice daily. Higher
dose medication and more slowly metabolized
enantiomers only minimally affect plasma/time
drug concentrations and still require meal-timed
administration. Twice daily dosing increases cost
of treatment, can negatively affect compliance, and
is currently not FDA approved, which makes in-
surance approval more difficult. Developing PPIs
with longer half-lives or ones that incorporate de-
livery technologies to prolong their absorption are
more rational ways to improve their pharmacol-
ogy and effectiveness. Longer half-life drugs in-
clude ilaprazole (3.6 h), which is currently mar-
keted in China, and tenatoprazole (8–14 h), which
has yet to reach the world market. Chemically me-
tered absorption (CMA) omeprazole (not yet mar-
keted), extended-release rabeprazole (FDA accepted
NDA 6/4/10), and dexlansoprazole-MR36 (available
in the United States) are examples of prolonged
absorption technologies. The later compound in-
corporates the more slowly metabolized dextro-
rotatory isomer of lansoprazole, (R)-lansoprazole,
with a pH-dependant dual-delayed release delivery
system.
The elimination half-life of dexlansoprazole is
about one to two hours, which is similar to other
PPIs, but the dual-delayed release formulation ex-
tends drug plasma time concentration to 10–12
hours,37 which in turn enhances its ability to con-
trol intragastric pH. PK and PD studies show that
dexlansoprazole-MR can be given without regard to
food and can be dosed any time of day. Such dosing
versatility is especially useful for patients who skip
meals (especially breakfast), who find it difficult to
dose medication before meal time, or who eat at
irregular times.
Clinical studies38 show that dexlansoprazole-MR,
60 mg, consistently heals all grades of erosive EE
during eight weeks of dosing. The 30-mg dose ef-
fectively maintained daytime and night symptom
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control and EE healing during 6 months of treat-
ment. The 30-mg dose also provides full 24-h
heartburn relief for patients with symptomatic
nonerosive GERD. The safety and tolerability pro-
files of both 60- and 30-mg doses are similar to
lansoprazole.
PPIs have inherent pharmacologic limitations,
short half-lives and a requirement for meal-related
dosing, which influences their effectiveness and pa-
tient compliance. Newer technologies that extend
PPI duration of action permit more versatile ad-
ministration.Whether these newermedications im-
prove compliance, overall effectiveness of acid sup-
pression, and clinical outcomes remains to be seen.
The only one of these newer drugs currently avail-
able in the United States, dexlansoprazole-MR, has
more convenient dosing, a longer duration of ac-
tion, consistent clinical efficacy, and excellent safety
and tolerability. In this regard, it does address some
of the unmet needs of the traditional PPIs.
9. How should issues regarding long-term
use of PPIs be considered?
Shoshana J. Herzig
sherzig@bidmc.harvard.edu
Since the introduction of omeprazole in 1988, the
use of PPIs has climbed rapidly. Although incident
use has been relatively stable in the last several years,
prevalent use of these drugs continues to increase,
reflecting increased numbers of long-term users.
Long-term use accounts for a large proportion of
use of these medications, if not the majority, de-
pending on the definition used—one study found
that 84% of PPI prescriptions are repeat prescrip-
tions.Up to half of initial prescriptions occur during
a hospitalization, and 50% are subsequently con-
tinued without any evaluation of efficacy/need to
continue. Although they are highly effective medi-
cations, research has consistently found that a large
proportion of PPI prescriptions are not indicated.39
Given these statistics, reports of risk have impor-
tant implications.AlthoughPPIs are relatively “safe”
medications for the individual patient, even a rela-
tively safe drug, if administered broadly, can become
“unsafe” from a public health standpoint.
Fundic gland polyps
The first reports of risk associated with PPIs came in
the mid-to-late 1990s when several case reports of
fundic gland polyps (FGPs) were published. Since
then, several large case-control and cohort stud-
ies have been conducted with somewhat conflict-
ing findings. Although most studies find increased
odds of FGPs in patients on PPIs, these odds ratios,
as well as the unexposed risk estimates, vary widely
among the studies, making interpretation difficult.
Furthermore, the clinical significance of FGPs is un-
certain, as most studies have found an exceedingly
low rate of associated dysplasia. Accordingly, the as-
sociation between PPIs and FGPs, should one exist,
does not have obvious clinical implications at the
present time. More research is necessary to more
conclusively define the association and determine
the clinical significance of such an association. Until
then, there does not seem to be a role for routine
surveillance endoscopy in patients on PPIs, other
than that associated with the clinical indication for
the medication.
Clostridium difficile infection
Studies have found that loss of stomach acidity is
associated with colonization of the normally sterile
upper gastrointestinal tract. Although Clostridium
difficile is relatively acid stable, it is possible that
survival of C. difficile spores may be facilitated by
reduced gastric acidity. Given reports of increased
risk of other enteric infections in patients on PPIs,
several cohort and case-control studies have inves-
tigated the association between PPIs and C. difficile
infection. A systematic review of 12 such studies
found an increased risk of taking antisecretory ther-
apy in those infected with C. difficile (pooled odds
ratio [OR] 1.94; 95% CI, 1.37–2.75).40
Community-acquired pneumonia
Increased bacterial colonization of the upper gas-
trointestinal tract may also predispose one to devel-
opment of pneumonia, as demonstrated in several
studies in ventilated patients.41 In addition, some
studieshavedemonstrated impaired leukocyte func-
tion in patients on PPIs. Given these findings, sev-
eral authors have investigated the association be-
tween PPIs and community-acquired pneumonia,
generally finding an association between current use
of PPIs and pneumonia, with ORs ranging from
1.02 to 1.9. An interesting finding in several stud-
ies is that there seems to be an inverse relation-
ship between the magnitude of the association and
the duration of exposure. Thus, patients who have
been on long-term PPI therapy may actually be at
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Table 2.Risks of long-term PPI therapy
Number exposed
annually in
the United Number
Risk NNTHa States harmed
C. difficile 2,400b 6 million 2,500
Hip fracture 1,200c 6 million 5,000
Pneumonia 22641 6 million 26,550
Fundic gland ?e
polyps
aNumber needed to harm.
bExtrapolated from Odds ratio = 2.9; unexposed event
rate = 22/100,000 persons.
cExtrapolated fromRef. 86. Odds ratio= 1.44; unexposed
event rate = 1.8/1000 person-years.
eOdds ratios, as well as unexposed risk estimates vary
widely among the studies, prohibitingNNTHcalculation.
less risk for community-acquired pneumonia than
patients in whom these medications have been re-
cently initiated.
Hip fractures
The biological plausibility of an association between
PPIs and hip fractures has been questioned, as the
role of pH in calcium absorption is controversial.
One large case-control study found an OR for hip
fracture in patients prescribed long-term (>1 year)
PPI of 1.44 (95% CI, 1.30–1.59). However, subse-
quent studies have failed to confirm this association,
including one study using the same data set, but
slightly different methods. Thus, given the contro-
versial biological plausibility, and conflicting find-
ings, there is insufficient evidence on which to base
any clinical recommendations. However, given that
vitamin D deficiency and osteoporosis are prevalent
in the elderly, all elderly patients, including those on
PPIs, should be reminded to assure adequate dietary
calcium intake.
Conclusions and implications
The clinical implications of these risks can best be
understood by calculating the numbers needed to
harm. Using the estimates of relative risk and un-
exposed incidence rate of the complication from
the major studies in each area, we can generate the
approximate numbers needed to harm as listed in
Table 2. With approximately 2% of the U.S. pop-
ulation on long-term PPIs at any given time, these
numbers needed to harm translate to approximately
34,000 patients potentially harmed annually in the
United States alone. Thus, although the risks are
small at an individual patient level, they are poten-
tially quite large from a population perspective.42
Although these risks have not been conclusively
demonstrated, the fact that such a large proportion
of prescriptions are not indicated, coupled with the
possibility of risk, should prompt us to reevaluate
prescribing practices.
More specifically, the need for long-term PPI
therapy should be periodically reevaluated. For
those who do require long-term therapy, the lowest
effective dose and the lowest effective level of acid
suppression should be used.43 Use of a histamine-
2 receptor antagonist should be considered instead
of a PPI, and a “step-up” approach should be used.
Older adults should be reminded to ensure adequate
dietary calcium intake, and consideration should be
given to calcium citrate and vitamin D supplemen-
tation. Finally, behavioral interventions for nonul-
cer dyspepsia should be encouraged, such as eating
smaller meals, weight loss, smoking cessation, and
head-of-bed elevation.
10. Should prokinetic agents, such as
dopaminergic antagonists, be considered
as a valuable addition to the treatment of
Barrett’s patients?
Takeshi Kamiya
kamitake@med.nagoya-cu.ac.jp
The answer to this question may be yes. GERD is a
major risk factor for BE and adenocarcinoma of the
esophagus. Patients with GERD, including reflux
EE, may develop BE, as the esophagus repeatedly
is exposed to acidic gastric contents. Adenocarci-
noma may develop from BE, a metaplastic change
of the esophageal epithelium from squamous to
intestinalized mucosa, which is associated with
chronic reflux.Unfortunately, there arenoevidences
of the efficacy of prokinetic agents in BE. Instead,
several reports concerning the role of prokinetics in
the treatment of GERD have been reported.
For example, 300 mg of itopride treatment
for 30 days showed a significant decrease in the
instances of acid reflux.44 Another report 45 is
about the effect of addition of a prokinetic agent
to PPI, in which after a 12-week treatment of PPI
alone, additional mosapride for 12 weeks showed
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significant improvement in GERD symptoms. One
randomized trial46 showed that a combination
of pantoprazole and mosapride is more effective
than pantoprazole alone in patients with erosive
GERD. In our study,47 GERD patients revealed
delayed gastric emptying, and mosapride showed
efficacy in GERD patients, especially in those with
disturbed gastric motility. In healthy volunteers,
two weeks’ intake of omeprazole resulted in delayed
gastric emptying, and concomitant administration
of tegaserod prevented delayed gastric emptying
induced by omeprazole monotherapy.48 This effect
may be seen in GERD or Barrett’s patients being
treated with omeprazole or other PPIs.
In conclusion, these data suggest that prokinetic
agents may be considered as a valuable addition to
the treatment of Barrett’s patients.
11. Is there a more effective proton pump
inhibitor in the obese patient with GERD?
Iva Pelosini and Carmelo Scarpignato
scarpi@tin.it
Obesity represents a worldwide problem that has
reached the status of an epidemic. According to the
latest estimates from the World Health Organiza-
tion, more than 1.5 billion adults worldwide are
overweight, and 400 million of these are clinically
obese (http://apps.who.int/bmi/index.jsp). Several
epidemiological studies have shown an association
between a patient’s higher body mass index (BMI)
and the risk of GERD symptoms and lesions
(http://www.medscape.org/viewarticle/560076).
There is also evidence to suggest that high BMI is
an independent risk factor for the development
of erosive EE and is associated with an increased
risk of esophageal adenocarcinoma. Data from
mechanistic investigations indicate that high BMI
may also predispose individuals to pathologic
gastroesophageal reflux. Indeed, many of the
pathophysiological mechanisms involved in adult
GERD are exaggerated in obesity. They include an
increased prevalence of hiatus hernia, negatively
affecting esophago-gastric junction integrity and
function, an increased number of transient LES
relaxations, increased intragastric pressure, and
impaired esophageal motility.
In spite of the well-documented evidence sup-
porting the association between obesity and GERD,
there is a surprising paucity of information in
the literature concerning the impact of over-
weight/obesity on the efficacy of acid-suppressive
therapies, such as histamine2-receptor antagonists
(H2RAs) and PPIs. Only recently have demographic
data (like BMI) been included in the analysis of the
results from clinical studies. The few available data
looking at body weight as prognostic indicator pro-
vide conflicting results.
Although it is known that obesity does af-
fect drug PKs and PDs (http://www.orthosupersite.
com/view.aspx?rid=19166), only few data are avail-
able in the literature dealingwith the clinical efficacy
of acid suppressive therapy (either H2RAs or PPIs)
and no one addressing their PK.
McDougall et al.49 first investigated the effect of
BMI and other demographic and clinical charac-
teristics on overall prognosis in a long-term (3–4.5
years), prospective study of 77 patients with GERD.
Patients requiring daily acid suppression at follow-
up had significantly higher mean BMIs than those
who did not (26.7 kg/m2 vs. 23.6 kg/m2; P = 0.001).
Logistic regressionanalysis found that increased age,
increased BMI, as well as initial diagnosis of EEwere
independently associated with an ongoing need for
chronic acid-suppressive therapy (P < 0.01).49 At
variance with these results, Talley et al.50 in a post
hoc analysis conducted on patients receiving PPI
therapy (omeprazole, 20 mg; esomeprazole, 20 or
40 mg daily) for NERD were unable to find an as-
sociation between baseline BMI and the probability
of patients reporting complete heartburn relief after
four weeks of treatment. In this study, however, pa-
rameters assessing rapidity of symptom relief were
not specifically investigated.
Two studies from the same group51,52 investigated
specifically the influence of BMI on PPI efficacy in
patients with erosive EE. In the first study, Sheu
et al.3 tried to relate demographic factors, including
BMI, to cumulative healing rates of patients with
severe EE (grades C and D according to Los Ange-
les classification) treated with esomeprazole (40 mg
daily) during a six-month period. They found that
a high BMI (≥25 kg/m2) was an independent risk
factor to determine mucosal healing by esomepra-
zole. Indeed, at the end of treatment, although 98%
of patients with a BMI < 25 kg/m2 were healed,
only 60% of those with a BMI ≥ 25 kg/m2 achieved
mucosal healing (P < 0.001). Multivariate logis-
tic regression analysis showed a 3.6-fold increase in
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Figure 7. Sustained symptomatic response to esomeprazole in
patients with Grade A-B reflux esophagitis, according to their
BMI value.
odds of healing for a decrease of BMI> 1.5 kg/m251
The second study,52 performed in patientswithmild
EE (A and B according to Los Angeles classifica-
tion), addressed the influence of body weight on the
efficacy of maintenance on demand therapy. Here
again, BMI influenced negatively the symptomatic
response to esomeprazole: the higher the patients’
BMI, the lower the number of patients with a sus-
tained symptomatic response (Fig. 7). A high BMI
also increased the need formedication (measured as
number of tablets taken eachmonth) and the failure
rate.52
A recent post hoc analysis53 was performed to
assess the effect of BMI on rabeprazole’s clinical
efficacy in patients with erosive GERD. The data
were derived from a comparative trial assessingmu-
cosal healing and symptom relief of rabeprazole and
omeprazole (both given at 20 mg daily) in patients
with mild to moderate erosive EE. Although there
were no significant differences between treatments
for the primary endpoint (i.e., healing of esophageal
lesions), rabeprazolewas significantlymore effective
than omeprazole for several secondary end points,
particularly those concerning time to symptom re-
lief. In patients with a BMI ≥ 25 kg/m2, the mean
time to first day of satisfactory heartburn relief (in-
tensity≤ 1) with rabeprazole 20mg (2.6± 0.3 days)
was significantly shorter versus that observed with
omeprazole, 20 mg (3.8 ± 0.4 days, P = 0.0113;
Fig. 8).
In patients with a BMI < 25 kg/m2, there was a
numerical trend in favor of rabeprazole compared
with omeprazole, but the difference fell short of sta-
tistical significance (3.1 ± 0.5 vs. 5.0 ± 0.9 days, re-
spectively;P = 0.1996). Similarly, significantlymore
patients taking rabeprazole in the overweight/obese
BMI category achieved satisfactory heartburn relief
in each of the first three treatment days compared
with patients who received omeprazole (59.2% vs.
46.6%; P = 0.0256). By contrast, in lean patients
no differences between rabeprazole and omeprazole
were found for this end point (rabeprazole, 52.7%;
omeprazole, 48.8%; P = 0.6065).
Although it is difficult to compare the results ob-
tained with various PPIs in different studies, due to
different patient populations and different exper-
imental design, the opposite behavior (better ver-
sus lower efficacy in GERD) of rabeprazole and
esomeprazole suggests that the influence of over-
weight/obesity on drug efficacy is molecule depen-
dent and does not represent a class effect. The rea-
sons underlying the observed difference between
these twoPPIs arenot clear butmay reflectunknown
PK changes in obesity. Either the volume of distri-
bution (Vd) and/or the hepatic catabolism of PPIs
could be altered in the obese patients. Indeed, large
variations of Vd of lipophilic drugs (as are PPIs)
and impaired cytochrome P450 activity (mainly
of the 3A subfamily) have been reported in obe-
sity (http://www.orthosupersite.com/view.aspx?rid
=19166). Unfortunately, no PK study has ever been
performed in this special patient population and,
given the obesity epidemic, this kind of study is
nowadays mandatory for all the widely used drugs.
Whatever the reason (be it PK or PD) and despite
the methodological limitations, this study shows
that the clinical efficacy of rabeprazole is main-
tained in overweight/obese patients with GERD
and suggests that this subgroup of patients may
derive from rabeprazole even greater benefit than
lean patients. Taking into account the comorbidities
Figure 8. Symptomatic relief with rabeprazole or omeprazole
inpatientswith erosive esophagitis, according to theirBMIvalue
(from Ref. 5).
128 Ann. N.Y. Acad. Sci. 1232 (2011) 114–139 c© 2011 New York Academy of Sciences.
Richter et al. Barrett’s esophagus: PPIs and chemoprevention II
(http://www. biomedcentral.com/1471-2458/9/88)
and consequent cotherapies, often needed in these
patients, the low propensity for drug-to-drug in-
teractions of rabeprazole makes this PPI particu-
larly suitable for obese patientswith any acid-related
diseases.
12. What is the role of baclofen, an agent
that blocks TLESR, in the treatment of
Barrett’s esophagus?
Roy K.H. Wong
roykhw@gmail.com
There are no data concerning the treatment of BE
with baclofen. Baclofen is a GABAB agonist, and
GABAB is a major inhibitory neurotransmitter in
the central nervous system. GABAB receptors are
located in the enteric nervous system and cen-
trally (brainstem). Baclofen inhibits TLESR through
vagal–vagal pathways that transmit impulses from
GABA receptors in the proximal stomach to the
brainstem in the nucleus tractus solitarius and dor-
sal vagal nucleus. These impulses are processed, and
efferent signals are sent through the vagus nerve to
GABA receptors in the LES.
Published studies on baclofen relate to its
effects on the LES and esophageal reflux in
Table 3.Effects of acute chronic baclofen therapy: acute GABAB agonist studies
Author n Patients Dose PR TLESRs Reflux episode
Lidums87 20 Healthy Baclofen 40 mg, 90
minutes prior
5.7 →2.2 1 → 0.3 LESP 8.7
→ 10.8
Zhang88 20 GERD Baclofen 40 mg, 90
minutes prior
15 → 9
(<0.002)
7 → 4, P < 0.02
Cange89 20 GERD Baclofen 10 mg,
BID× 24 hours
16.5 → 7.9, P <
0.0001 24 hours
Ciccaglione90 15 GERD Baclofen 40 mg GERD 149 → 73,
P < 0.003
9 Control Control 42 → 18,
P < 0.007
Vela91 9 GERD Baclofen 0.5 mg/kg 7.6 → 3.6, P
< 0.05
15 → 6 acid reflux,
P < 0.004; 4 → 2
nonacid, P <
0.003
9 Control 7 → 1 acid reflux,
P < 0.02; 2 → 0
nonacid, P <
0.005
Omari92 30 GERD,
children
ages 2–17
Baclofen 40 mg, 90
minutes prior
4.2 → 1.7, P <
0.05; 114 →61,
P < 0.05 (24
hours)
Boeckxstaens54 21 GERD 63%
EE
continued
PPI
Lesogaberan 65 mg
PO 1dose Q12×
3 ↑ LESp 28%
15.5→11.6
(↓25%)
Upright 25 → 12
episodes; supine
4.3 → 1 episode
Gerson55 44 GERD 3x/wk
20 Reflux
Epi./2
hours
Arbaclofen 10, 20,
40, 60 mg qd, 2
hours before
meal
60.9 → 50.5,
(17%). All doses
P < 0.005,
monitored for
12 hours
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Table 4. Summary of four semichronic baclofen studies that ranged from two to four weeks
Total
number
reflux Time pH
Author n Patients Dose Duration episodes < 4 Symptom
Koek93 16 GERD + 20 mg QID 14 days OMP vs. OMP OM P vs. Improved
Bile Reflux graded 4 + B 14 → 17 OMP + P < 0.01
OMP 20 (NS) DGER B (NS)
mg BID 17 → 12 (<
0.05)
Ciccaglione94 10 10 mg QID 220 → 52 5.8 → 2.7 Improved
(P < P < P <
0.003) 0.02 0.0007
Kawai95 8 GERD Peds 0.7 mg/ 7 days 24 hours (P NS
(neurologically kg/day < 0.01) PR
impaired) (P < 0.049)
Cossentino98 43 GERD 20 mg 14 days 69 → 47, Total, P < Significantly
PO TID P < 0.045, 0.003, improved
PP episodes, upright, P
P < 0.04 P < 0.016
normalpatients and thosewith reflux. Six studies are
short-term studies, lasting a few hours during the
pre- and postprandial period to 24 hours (Table 3).
Two studies concern lesogabaran54 and arbaclofen
(R isomer of baclofen),55 compounds similar to ba-
clofen. One of the six studies was performed in chil-
dren (Omari). In five studies, baclofenwas adminis-
tered as a single dose (30–40 mg) 90 minutes before
a meal; in one study baclofen, 10 mg twice daily,
was administered, and patients were monitored for
24 hours. Lesogaberan, 65 mg, was given every 12
h, three doses, and administered with PPIs. Arba-
clofen, 10, 20, 40, and 60 mg, was administered as
a dose-ranging study and monitored for reflux for
12 h following the initial dose. Seven of eight stud-
ies showed a significant decrease in reflux episodes
(except lesogaberan). All four studies that moni-
tored TLESRs showed a decrement in TLESRs, with
two being significantly different from controls or
placebo.
There have been only four semichronic ba-
clofen studies that ranged from two to four weeks
(Table 4). One study was in neurologically impaired
children. The doses of baclofen in the four stud-
ies ranged from 10 mg, po qid, to 20 mg, po tid
to qid. Baclofen was the only antireflux agent in
all studies except for one (Ref. 56) that continued
omeprazole use. In the Koek study, duodenogas-
troesophageal reflux was measured with a Bilitec
probe, as these patients were symptomatic in spite
of PPI therapy. Four of four studies showed sig-
nificant decreases in reflux episodes, whereas three
of four showed significant improvement in reflux
symptoms. The Koek study showed significant im-
provement in duodenogastroesophageal reflux but
not esophageal reflux.
One study by Orr et al.57 looked at baclofen or
placebo and was given to reflux patients before
sleep at night. Polysomnography was performed
over a two-day period. Although there was no dif-
ference in acid contact time, the number of re-
flux events, sleep time, and sleep efficiency was
significantly improved in the baclofen-treated pa-
tients.This suggests thatbaclofenmay facilitate sleep
in GERD patients without increasing acid contact
time.
In conclusion, although baclofen has been shown
to decrease TLESRs specifically in the postprandial
state, there are a few studies to suggest that it may
be effective in supine reflux and duodenogastroe-
sophageal reflux. Semichronic studies have shown
symptomatic efficacy.
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13. What is the comparative effect of
proton pump inhibitors on nocturnal acid
breakthrough?
David Armstrong
armstro@mcmaster.ca
Acid suppression therapy for patients with ero-
sive EE produces healing rates that are propor-
tional to the degree and duration of acid sup-
pression achieved. PPIs, given once daily, produce
marked suppression of gastric acid secretion and
gastric acidity that is significantly greater than that
produced by histamine H2-receptor antagonists
(H2-RAs), achieving healing in 80–90% of patients
within eight weeks. Despite this, esophageal ero-
sions and reflux symptoms persist in a proportion of
patients receiving once-daily PPI therapy. Divided-
dose PPI therapy produces greater acid suppression
but recurrent or “breakthrough” acid secretion is
well documented even in individuals receiving a PPI
twice daily.58
Nocturnal acid breakthrough (NAB) has been
defined, arbitrarily, as the persistence of an intra-
gastric pH below 4, for at least one hour, within
12 h of the intake of a PPI in the evening.1 The
initial report of NAB indicated that acid break-
through occurred approximately 7.5 h after the
evening PPI dose, regardless of whether the sub-
jects received omeprazole or lansoprazole.58 On
the basis of these data, it was proposed that NAB
is a class effect, attributable to the PKs of the
most common, currently available, delayed-release
(DR) PPIs—esomeprazole, lansoprazole, omepra-
zole, pantoprazole, and rabeprazole—which have a
short t 1
2
(0.5–1.5 h) and a short tmax (1.0–3.5 h).59
As a consequence, there is little PPI prodrug avail-
able to inhibit new or newly activated proton pumps
once seven to eight hours have elapsed since the last
intake of drug.
Although the majority of currently available DR
PPIs have similar PK properties, they differ with re-
spect to the duration of acid suppression—defined
as an intragastric pH below 4.0—achieved when
they are given once daily. In a five-way, cross-over
studyofonce-daily, standard-doseDRPPIs, the time
during which intragastric pH remained above 4.0,
at steady state, ranged from 10.1 h for pantoprazole,
40 mg daily, to 14.0 h for esomeprazole, 40 mg
daily.60 These differences were also evident in a
meta-analysis that included data from 57 studies
in an evaluation of the acid suppression produced
by the same five DR PPIs at a variety of daily
doses (Table 5). The extent of persistent acid sup-
pression, presented as the time during which gas-
tric pH was below 4.0, was dose dependent, rang-
ing from 10.5 h (esomeprazole, 20 mg) to 19.6 h
(omeprazole, 10mg daily) at “half-dose,” from8.5 h
(esomeprazole, 40 mg) to 12.3 h (omeprazole, 20
mg daily) at “standard-dose” and from 3.6 h (es-
omeprazole, 80 mg) to 8.8 h (omeprazole, 40 mg
daily) at “double-dose;” the relative potencies of the
DR PPIs, compared to omeprazole, were reported
as 0.23, 0.90, 1.00, 1.60, and 1.82 for pantopra-
zole, lansoprazole, omeprazole, esomeprazole, and
rabeprazole, respectively.61 This analysis did not,
however, evaluate the effect of twice-daily DR PPI
administration, and it is not, therefore, applicable
directly to the relative effects of different PPIs on
NAB.
The effect of twice-daily dosing on nocturnal acid
suppression, in particular, was evaluated in an anal-
ysis of 16 PD studies, with 31 arms, of the effects
of standard dose DR PPIs administered twice daily
on intragastric pH at steady state (i.e., for five to
eight days) in healthy subjects. Consistent with the
results of previous studies, this analysis (Table 6)
reported times (%) with intragastric pH below
4.0 of 15.4% and 19.0% for esomeprazole (40 mg
Table 5.Time (% 24-h period) with gastric pH below 4.0: meta-analysis of gastric pH data at steady state in healthy
subjects61
PPI Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole
Dose 40 mg 30 mg 20 mg 40 mg 20 mg
Half 43.7 54.1 81.7 57.6 48.8
Standard 35.4 44.9 51.3 46.4 42.3
Double 15.1 35.3 36.8 29.2 29.2
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twice daily) and omeprazole (20 mg twice daily),
respectively, compared with 35.1% and 36.4% for
lansoprazole (30 mg twice daily) and pantoprazole
(40 mg twice daily), respectively62; no comparative
data were available for rabeprazole.
In conclusion, the data available for currently
availableDRPPIs indicate that gastric acid secretion
returns, to an important extent, in a high propor-
tion of individuals receiving standard, once-daily
DR PPIs and that this is not abolished by twice-
daily administration. Although there are limited
data relevant, specifically, to the definition of NAB,
the comparative effects of the different DR PPIs, at
approveddoses, seem tobe similar for 24-h acid sup-
pression, nocturnal acid suppression, andnocturnal
acid breakthrough; thus, on the basis of the analysis
of 24-h intragastric pH for the five DR PPIs,4 es-
omeprazole and rabeprazole are similar in potency,
and more potent than omeprazole and lansopra-
zole, which are, themselves, similar in potency and,
in turn, more potent than pantoprazole.4
Newer PPIs, formulated for delayed release—for
example, dexlansoprazole and AGN 201904-Z—or
characterized by a longer half life—for example, S-
tenatoprazole (STU-Na)—appear to reduce noctur-
nal intragastric acidity to a greater extent than cur-
rent DR PPIs, when given once daily.2 Despite this,
nocturnal return of gastric acid secretion is a com-
mon phenomenon, regardless of the PPI and ad-
ministration frequency. A fall in intragastric pH at
night may be characterized as nocturnal acid break-
through; however, because NAB is defined in the
contextof twice-dailyPPI administration,morepre-
cise quantification of nocturnal intragastric acidity
(e.g., time with gastric pH below 4.0) may yield a
better understanding of the effect of newer agents
on nocturnal acid secretion and their therapeutic
effect in GERD.
14. Compared to PPIs given at bedtime,
what are the advantages of the low
overnight gastric and esophageal acidity
observed with immediate release
omeprazole?
Kenneth R. DeVault
devault.kenneth@mayo.edu
Until recently, all PPIs were enteric coated to enable
delivery and release of the agent in the proximal
Table 6.Mean time (% 24-h period, % daytime, % night-
time) with gastric pH below 4.0: meta-analysis of gastric
pH data at steady state (day 5 to day 8) in healthy sub-
jects62
Mean time (%) gastric pH < 4.0
Dose
[number of study arms, number of
subjects]
24-hour period Daytime Nighttime
Esomeprazole 15.2 19.0 15.4
40 mg bid [2, 55] [1, 25] [2, 55]
Lansoprazole 30.5 7.0 35.1
30 mg bid [2, 22] [1, 12] [1, 12]
Omeprazole 19.1 23.7 19.0
20 mg bid [3, 39] [1, 16] [3, 38]
Pantoprazole 29.2 – 36.4
40 mg bid [1, 30] [1, 30]
Rabeprazole 10.4 – –
20 mg bid [2, 23]
small bowel. These agents suppress acid for up to
15hper daywhengivenoncedaily andup to 19hper
day when given more than once daily. In addition,
most agents take three to five days to reach steady
state and aremost effectivewhen takenbeforemeals.
A new formulation of nonenterically coated
omeprazole combinedwith sodiumbicarbonate has
been developed. Sodium bicarbonate is required in
this preparation to protect the omeprazole from
degradation by stomach acid and also seems to
stimulate proton pumps enabling them to be effi-
ciently blocked by the PPI. This combination has
been described as immediate-release omeprazole
(IR-OME).63 IR-OME was originally marketed as
a powder to be constituted with water but is now
also available in capsules containing 20 or 40 mg
of omeprazole combined with sodium bicarbon-
ate. The PDs of this combination has been well
studied in healthy volunteers where both the max-
imal concentration of the PPI was higher and oc-
curred earlier after ingestion than the more tradi-
tionally formulated PPIs.64
A potential advantage of this medication is noc-
turnal use. IR-OME taken at bedtime has been
shown to control 24-h and nighttime gastric acid
more completely than pantoprazole taken once or
twice daily.65 On the twice daily dose, the 24-h
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acid exposure was 12.2% for IR-OME and 43% for
pantoprazole, whereas the overnight acid exposure
was 8.0% and 63.5%, respectively. Another prelim-
inary study compared nocturnal doses of OME-IR,
40 mg; lansoprazole, 30 mg; and esomeprazole,
40 mg.66 Although 92% of patients experienced
NAB when treated with either lansoprazole or es-
omeprazole, only 61% of patients experienced NAB
when treated with OME-IR. This was mainly re-
lated to the lower acid early in the evening (likely
due to a combination of neutralization by the bicar-
bonate and more rapid absorption of the omepra-
zole). A downside of this medication is the relatively
high sodium load (460 mg in each 40 mg omepra-
zole dose), especially when taken more than once
daily.
In summary, IM-OME has several advantages
over enterically coated PPIs. It has outstanding noc-
turnal acid control when given twice daily and can
provide very good acid support when given at bed-
time. An additional advantage is the option to take
themedication independent of food consumption.
15. Is combination of PPIs with
antinflammatory drugs (NSAIDs) and
aspirin to be considered the future of
chemoprevention in BE?
Paolo Bechi, Antonio Taddei, Giancarlo Freschi,
Maria Novella Ringressi, Duccio Rossi
Degli’Innocenti, Francesca Castiglione, and
Emmanuella Masini
antonio.taddei@unifi.it
Many potential agents for esophageal adenocarci-
noma chemoprevention in BE have been suggested,
but those for which substantial evidence of ef-
fectiveness in humans has been shown are PPIs
and NSAIDs. The rationale for PPIs in chemopre-
vention comes first from the well-recognized role
of GERD in the multistep process of esophageal
adenocarcinogenesis and second from limited
observational data that demonstrated an association
of PPI use and the reduced incidence of dysplasia in
BE.67 The rationale for aspirin use in chemopreven-
tion comes from its action as a nonselective COX-2
inhibitor, thus preventing COX-2 proinflammatory
and carcinogenetic effects exerted through an in-
crease in cell proliferation, inhibition of apoptosis,
and activation of angiogenesis. In this respect, selec-
tive COX-2 inhibitors such as the coxib family have
been most widely studied and have appeared for
a, although the most promising drugs in this par-
ticular application. However, some agents in this
family seem to be responsible for heavy cardiovas-
cular side effects; thus, their use in this chemo-
preventive application does not seem any longer
justified. Moreover, aspirin has a chemopreven-
tion efficacy for esophageal cancer more than other
NSAIDs (efficacy of 40%). Therefore, aspirin has
the best risk–benefit ratio, especially for esophageal
cancer.68
The rationale for the association in chemopreven-
tion of aspirin with PPIs is provided by the symp-
tomatic improvement induced by PPIs in patients
with BE suffering fromGERD; in other words, most
of these patients would take PPI medication any-
way, and PPIs reduce the risk of upper gastroin-
testinal complications due to NSAIDs (from 4% to
1.5% per year for aspirin). The AspECT trial has
been devised to answer our question. The aim of
the AspECT trial is to verify the efficacy of chemo-
prevention with PPIs and/or aspirin in BE metapla-
sia. It is the biggest multicenter controlled trial and
has reached its target of 2,500 patients. It is now
in its fourth year, and its results, due in 2016 with
an interim analysis in 2011 and 2012, are expected
to be decisive. Effects of therapy on mortality and
conversion rate from Barrett’s metaplasia to high-
grade dysplasia or adenocarcinoma will be regis-
tered. Indications are also expected concerning the
best age tobegin the treatment, dosage, andduration
of therapy.However, so far there is no evidence from
long-term randomized controlled studies regarding
the use of PPIs and/or aspirin to reduce the risk
of esophageal adenocarcinoma. Looking forward to
2016, to support our conclusion regarding chemo-
preventionwith PPIs and aspirin, we do not yet have
a long-term randomized controlled study, but only
inconclusive epidemiological data;69 however, very
important but indecisive clinical and experimental
data are available.70,71
Personal, preliminary experience
We studied PPIs and aspirin effects on isolated cells
from mucosal biopsies in seven patients with BE
metaplasia (unpublished data). Proliferative activ-
ity was studied by means of tritiated thymidine
incorporation. After the EGF stimulus, which ob-
viously determines a very significant increase in
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Figure 9. Proliferative activity measured by means of tritiated thymidine incorporation before and after EGF stimuli in BE
samples.
proliferative activity, both aspirin and omepra-
zole, when separately preincubated, were capable of
showing a similar decrease in proliferative activity.
The incubation with both aspirin and omeprazole
at the same time induced a decrease in proliferative
activity significantly greater than that induced sepa-
rately by any of the two drugs. This seems a demon-
stration of a synergistic effect of the two drugs (un-
published data) (Fig. 9). The same findings were
shown by means of the immunohistochemical eval-
uation. Moreover, pretreatment of the cells with as-
pirin alone significantly reduced the expression of
the receptor of EGF (EGFR); this effect was signifi-
cantly greater when omeprazole was added, whereas
the effects of aspirin on proliferative activity are
well known and due to its action as a nonselective
COX-2 inhibitor (unpublished data). The effect of
omeprazole on proliferative activity could be medi-
ated by the lowering of intracellular pH, of which
omeprazole has been shown to be capable in our
experiments. Lowering of intracellular pH seems to
increase caspase-3 activity, which, in turn, could af-
fect apoptosis and proliferative activity.
In conclusion, looking forward to the AspECT
trial, no trial has so far definitely shown the efficacy
of any kind of chemoprevention in BE. However,
relevant, but indecisive clinical and experimental
data support the association of aspirin/PPIs, which
on the basis of our experiments seem potentially
capable of a synergistic effect.
16. What can be the expected effect from
new PPI drugs currently under
investigation on prolonged plasma
concentration of drug and intake
regardless of meal timing?
Richard H. Hunt
huntr@mcmaster.ca
Therapeutic acid suppression in GERD is used to
control symptoms, heal erosive EE, and more re-
cently to prevent the evolution and progression
of Barrett’s metaplasia. It is known that exposure
to gastric acid increases cell proliferation in the
distal esophagus and that there is a synergistic effect
of acid when combined with bile on cell prolifera-
tion.Moreover, there is some evidence that pulsatile
esophageal acid exposure increases an undifferenti-
ated cell phenotype, although continuous acid ex-
posure does the opposite.72,73 Some of the effects of
acid are summarized in Figure 10A.
One of the many remaining questions is whether
pH is important, and, if so, what pH? We know
that during standard dosing of current DR PPIs
given twice daily in healthy volunteers, there is in-
creased intragastric acidity for up to one-third of the
nighttime. After esomeprazole, 40 mg twice daily
for five to eight days, results showed that 15% of
the nighttime intragastric pH was <4.74 Moreover,
other studies show that ∼60–80% of patients have
persistent nocturnal acidification despite twice daily
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Figure 10. PPIs and cancer risk in Barrett’s esophagus.
PPIs,75 and ∼25% patients with reflux symptoms
do not respond to twice daily PPIs given for four to
eight weeks.76 In GERD patients who are refractory
to PPIs, pH was abnormal at 30% for once-daily
PPIs, and in 25% of patients on twice-daily PPI.77
Certainly, in healthy volunteers taking esomepra-
zole, 40 mg once daily 30 min before breakfast, the
intragastric pH is < 4 for 75% of the time between
midnight and0700hours, but ofmore concern is the
fact that pH is<2 forover 40%of that time (2.87hor
172 min) (Fig. 10B).78 Thus, there are now a num-
ber of new antisecretory drugs under development
by the pharmaceutical industry, and these have
recently been reviewed by Scarpignato and Hunt
(Fig. 11A).79
In short, of those drugs recently introduced or
likely to be seen in clinical development in the
near future, these include new formulations of ex-
isting drugs, such as dexlansoprazole; novel chem-
ical entities, such as tenatoprazole or API-023; or
the new class of potassium channel blocking drugs.
Dexlansoprazole has recently been introduced in
both the United States and Canada; results show
a modest increase in plasma residence time and
AUC in the fed versus fasting state, thus prolong-
ing the antisecretory effect and removing the ab-
solute necessity for giving the drug before food,
which offers an important advantage in patients
with complex GERD.80,81 However, it is hard to de-
termine a clinically meaningful difference in mean
intragastric 24-h pH. Both API-023, previously
known as AGN 201904Z, and the sodium salt of
the S-isomer of tenatoprazole, STU-Na, have been
shown to predictably and consistently maintain an
intragastric pH ≥ 4 throughout the 24-h period
(Fig. 11B).82,83
The last class of drugs mentioned here in-
cludes the potassium-channel acid-blocking drugs
or PCABs, which include AZD-0865, which was
a short-acting compound with some toxicological
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Figure 11. New anti-secretory drugs with long plasma residence time.
problems that resulted in its being withdrawn from
development.84 Acurrent long-actingPCAB isTAK-
438, which has an impressive dose-dependent 24-h
antisecretory profile and remains in development in
Japan.85
Thus, the prospect of truly once-daily antisecre-
tory drugs is now real, and they offer a lack of
significant food interaction and an overall consis-
tent acid control with less pulsatile acid exposure
and improved control of nighttime acid secretion
that avoids the time period of nocturnal acidifi-
cation with fewer episodes of so-called “nocturnal
acid breakthrough.” The potential benefit of this
new generation of antisecretory drugs is designed
to prevent GERD complications, including ulcera-
tion and stricture, but particularly in preventing the
progression of BE.
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